Sagimet to Present Data from Phase 2 FASCINATE-1 Trial of TVB-2640 in NASH at AASLD’s The Liver Meeting 2021

SAN MATEO, Calif.: SAN MATEO, Calif., Oct. 4, 2021 /PRNewswire/ -- Sagimet Biosciences, a clinical-stage biotechnology company, announced today that consolidated results from its Phase 2 FASCINATE-1 trial of TVB-2640 in patients with nonalcoholic steatohepatitis (NASH) in the U.S. and China will be shared at The Liver Meeting 2021 of...

Click to view original post